NERV Investors Who Stayed The Course Reap Rewards...

(RTTNews) - Shares of Minerva Neurosciences Inc. (NERV) rocketed up over 270% on Thursday, touching a new high of $13.22, thanks to positive phase II trial results of its drug candidates MIN-101 and MIN-117.

MIN-101 is being developed for schizophrenia while MIN-117 is being tested in the indication of major depressive disorder.

In a phase IIb, 12-week trial of MIN-101 monotherapy in patients with negative symptoms of schizophrenia, the primary endpoint of statistically significant benefit in improving negative symptoms as measured by the pentagonal structure model (PSM) of the Positive and Negative Syndrome Scale (PANSS) was achieved.

In a phase IIa clinical trial in major depressive disorder, MIN-117 demonstrated superiority over placebo as measured by change in the Montgomery-Asberg Depression Rating Scale.

We alerted our Premium subscribers regarding this stock through a report titled "High Risk, High Reward..." when it was priced around $4.85. Had you bought the stock then and continued to hold it, you would have made a gain of at least 143% based on yesterday's closing price of $11.80.